MRSH Marsh & Mclennan Companies (MRSH) Insider Trading, Ownership & Congress Trades
Insurance · Insurance agents, brokers & service · CIK 0000062709
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
633
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $2.5M priced
What the filings say about MRSH
Insiders, 180 days
-$12.0M net sold
8 sellers · 33% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-09-23
Planned sales (Form 144), 90 days
$5.8M
6 notices
Marsh & Mclennan Companies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MARSH & MCLENNAN COMPANIES, INC. insiders sold a net $12.0M of stock across 12 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 44.9% of the 2,705 shares held after it.
- 1 other insider sold within 30 days.
- 633 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Vice President and Controller Mills Stacy sold about $243.0K of MRSH under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 633 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 20.0% of the 20,935 shares held after it.
- 1 other insider sold within 30 days.
- 633 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO, Marsh RE Klisura Dean Michael sold about $838.8K of MRSH under a 10b5-1 plan on Oct 23, 2026; 1 other insider sold within 30 days and 633 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 2, 2026.
- The trade is 14.3% of the 116,811 shares held after it.
- 2 other insiders sold within 30 days.
- 633 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Doyle John Q sold about $3.1M of MRSH under a 10b5-1 plan on Sep 2, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 633 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 16.3% of the 7,330 shares held after it.
- 2 other insiders sold within 30 days.
- 633 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and General Counsel Brennan Katherine sold about $224.9K of MRSH on Sep 2, 2026; 2 other insiders sold within 30 days and 633 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 11, 2026.
- The trade is 439.8% of the 1,478 shares held after it.
- 5 other insiders sold within 30 days.
- 633 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Marketing Officer Jones John Jude sold about $1.2M of MRSH on Aug 6, 2026; 5 other insiders sold within 30 days and 633 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$12.0M over 180 days
-$5.8M over 90 days
below 74% of Insurance
Congress
no House purchase disclosed in the last 12 months
Funds
633 funds bought in last quarter
more than 91% of Insurance
Revenue
+10.3% year over year
more than 53% of Insurance
Margin
15.4% net margin
more than 63% of Insurance
Buybacks
$2.0B repurchased, FY to 2026-09-30
more than 98% of Insurance
Short interest
1.3% of the float short (float per yahoo 2026-10-26) · 1.9 days to cover · settled 2026-09-30
below 81% of Insurance
What changed in the last 30 days
Oct 26President & CEO, Marsh RE Klisura Dean Michael sold $838.8K under a 10b5-1 plan (Oct 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 26Vice President and Controller Mills Stacy sold $243.0K under a 10b5-1 plan (Oct 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 23Officer Klisura Dean Michael filed to sell $838.8K by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 23Officer Mills Stacy filed to sell $243.0K by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13Rep. Kevin Hern sold $50K to $100K, disclosed 20 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch MRSH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MRSH: institutional holders (13F)
13F holdings, latest reported quarter
39,502,046 sh
$6.6B
31,472,575 sh
$5.2B
22,401,676 sh
$3.7B
18,122,340 sh
$3.0B
16,975,238 sh
$2.8B
Congress trades in MRSH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-23 · disclosed 20 days later
$50,001 - $100,000
Sold 2026-09-17 · disclosed 26 days later
$50,001 - $100,000
Sold 2026-09-14 · disclosed 11 days later
$1,001 - $15,000
Sold 2026-09-09 · disclosed 16 days later
$100,001 - $250,000
Sold 2026-09-02 · disclosed 23 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MRSH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Klisura Dean Michael
Filed 2026-10-23
$838.8K
Mills Stacy
Filed 2026-10-23
$243.0K
Brennan Katherine
Filed 2026-09-02
$224.9K
Doyle John Q
Filed 2026-09-02
$3.1M
Jones John Jude
Filed 2026-08-06
$1.2M
MRSH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco KBW Property & Casualty Insurance ETF
$18.1M position · as of 2026-05-31
7.5%
Oakmark Select Fund
$470.2M position · as of 2026-06-30
5.7%
Artisan Select Equity Fund
$4.7M position · as of 2026-06-30
4.8%
American Century Focused Large Cap Value ETF
$15.9M position · as of 2026-05-31
4.5%
Select Insurance Portfolio
$24.4M position · as of 2026-05-31
4.2%
The Jensen Quality Growth Fund Inc
$121.6M position · as of 2026-05-31
4.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Homeland Security
CONTRACTOR SUPPORT TO FACILITATE A PROPERTY OWNER'S INSURANCE AGENT OBTAINING FLOOD INSURANCE FOR TH · 2022-09-30
$97.3M
Pension Benefit Guaranty Corporation
INVESTMENT CONSULTING SERVICES · 2022-09-01
$6.0M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · John QDoyle
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$19.1M
$31.2M
$7.2M
+69%
+35%
2022
$30.9M
$23.2M
$8.1M
+46%
+21%
2021
$21.5M
$89.8M
$7.0M
+51%
+35%
2020
$19.7M
$19.0M
$6.3M
+7%
-2%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $12.0M sold by insiders over 180 days, 633 funds added last quarter, $5.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MRSH financials
Revenue growth
+10.3%
XBRL, annual
Net margin
15.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$28.5B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM MRSH
| FY Dec 2025 | $27.0B |
| FY Dec 2024 | $24.5B |
| FY Dec 2023 | $22.7B |
| FY Dec 2022 | $20.7B |
| FY Dec 2021 | $19.8B |
| Sep 2026 | $6.9B |
| Jun 2026 | $7.4B |
| Mar 2026 | $7.6B |
| Dec 2025 | $6.6B |
| Sep 2025 | $6.4B |
| Jun 2025 | $7.0B |
| Mar 2025 | $7.1B |
| Dec 2024 | $6.1B |
At each fiscal year end
Single quarter
Net margin, TTM
+14.2%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM MRSH
| FY Dec 2025 | +15.4% |
| FY Dec 2024 | +16.6% |
| FY Dec 2023 | +16.5% |
| FY Dec 2022 | +14.7% |
| FY Dec 2021 | +15.9% |
| Sep 2026 | +11.8% |
| Jun 2026 | +17.1% |
| Mar 2026 | +15.1% |
| Dec 2025 | +12.4% |
| Sep 2025 | +11.8% |
| Jun 2025 | +17.4% |
| Mar 2025 | +19.6% |
| Dec 2024 | +13.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.2B
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM MRSH
| FY Dec 2025 | $5.0B |
| FY Dec 2024 | $4.0B |
| FY Dec 2023 | $3.8B |
| FY Dec 2022 | $3.0B |
| FY Dec 2021 | $3.1B |
| Sep 2026 | $1.4B |
| Jun 2026 | $1.5B |
| Mar 2026 | -$750.0M |
| Dec 2025 | $2.1B |
| Sep 2025 | $2.0B |
| Jun 2025 | $1.6B |
| Mar 2025 | -$677.0M |
| Dec 2024 | $1.9B |
At each fiscal year end
Single quarter
Debt to equity
1.38x
long-term 2026-09-30 plus current 2026-09-30; equity 2026-09-30
Debt to equity MRSH
| FY Dec 2025 | 1.28x |
| FY Dec 2024 | 1.47x |
| FY Dec 2023 | 1.09x |
| FY Dec 2022 | 1.07x |
| FY Dec 2021 | 0.98x |
| Sep 2026 | 1.38x |
| Jun 2026 | 1.33x |
| Mar 2026 | 1.39x |
| Dec 2025 | 1.28x |
| Sep 2025 | 1.27x |
| Jun 2025 | 1.23x |
| Mar 2025 | 1.44x |
| Dec 2024 | 1.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.22x
TTM operating cash flow over long-term 2026-09-30 plus current 2026-09-30
Cash flow to debt MRSH
| FY Dec 2025 | 0.27x |
| FY Dec 2024 | 0.22x |
| FY Dec 2023 | 0.32x |
| FY Dec 2022 | 0.30x |
| FY Dec 2021 | 0.32x |
| Sep 2026 | 0.22x |
| Jun 2026 | 0.25x |
| Mar 2026 | 0.25x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.26x |
| Jun 2025 | 0.25x |
| Mar 2025 | 0.22x |
| Dec 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+26.7%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity MRSH
| FY Dec 2025 | +28.8% |
| FY Dec 2024 | +31.3% |
| FY Dec 2023 | +32.5% |
| FY Dec 2022 | +27.8% |
| FY Dec 2021 | +30.7% |
| Sep 2026 | +26.7% |
| Jun 2026 | +25.3% |
| Mar 2026 | +27.0% |
| Dec 2025 | +28.8% |
| Sep 2025 | +28.2% |
| Jun 2025 | +27.9% |
| Mar 2025 | +30.1% |
| Dec 2024 | +31.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.8%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets MRSH
| FY Dec 2025 | +7.2% |
| FY Dec 2024 | +7.8% |
| FY Dec 2023 | +8.2% |
| FY Dec 2022 | +6.9% |
| FY Dec 2021 | +8.2% |
| Sep 2026 | +6.8% |
| Jun 2026 | +6.7% |
| Mar 2026 | +6.8% |
| Dec 2025 | +7.2% |
| Sep 2025 | +7.6% |
| Jun 2025 | +7.7% |
| Mar 2025 | +7.7% |
| Dec 2024 | +7.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+13.9%
operating income after a 23.3% effective tax rate, over long-term 2026-09-30 plus current 2026-09-30 plus average of 2025-09-30 and 2026-09-30 minus cash
Return on invested capital MRSH
| FY Dec 2025 | +15.1% |
| FY Dec 2024 | +14.6% |
| FY Dec 2023 | +17.7% |
| FY Dec 2022 | +15.5% |
| FY Dec 2021 | +16.9% |
| Sep 2026 | +13.9% |
| Jun 2026 | +13.3% |
| Mar 2026 | +13.5% |
| Dec 2025 | +15.1% |
| Sep 2025 | +14.7% |
| Jun 2025 | +14.1% |
| Mar 2025 | +13.7% |
| Dec 2024 | +14.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+16.1%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed MRSH
| FY Dec 2025 | +16.7% |
| FY Dec 2024 | +17.8% |
| FY Dec 2023 | +19.4% |
| FY Dec 2022 | +13.5% |
| FY Dec 2021 | +13.5% |
| Sep 2026 | +16.1% |
| Jun 2026 | +15.6% |
| Mar 2026 | +15.9% |
| Dec 2025 | +16.7% |
| Sep 2025 | +18.1% |
| Jun 2025 | +17.7% |
| Mar 2025 | +17.8% |
| Dec 2024 | +17.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
23.62x
close 2026-10-23 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing MRSH
| FY Dec 2025 | 22.01x |
| FY Dec 2024 | 25.94x |
| FY Dec 2023 | 25.16x |
| FY Dec 2022 | 27.49x |
| FY Dec 2021 | 28.36x |
| Sep 2026 | 20.42x |
| Jun 2026 | 20.38x |
| Mar 2026 | 21.68x |
| Dec 2025 | 22.01x |
| Sep 2025 | 24.16x |
| Jun 2025 | 26.22x |
| Mar 2025 | 29.91x |
| Dec 2024 | 25.94x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$112.6B
market value at close 2026-10-23 on 2026-10-12 shares, plus long-term 2026-09-30 plus current 2026-09-30, minus cash 2026-09-30
Enterprise value MRSH
| FY Dec 2025 | $107.8B |
| FY Dec 2024 | $121.9B |
| FY Dec 2023 | $103.5B |
| FY Dec 2022 | $92.1B |
| FY Dec 2021 | $97.0B |
| Sep 2026 | $100.2B |
| Jun 2026 | $99.2B |
| Mar 2026 | $103.0B |
| Dec 2025 | $107.8B |
| Sep 2025 | $116.1B |
| Jun 2025 | $125.8B |
| Mar 2025 | $138.8B |
| Dec 2024 | $121.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.4%
TTM free cash flow over market value at close 2026-10-23
FCF yield MRSH
| FY Dec 2025 | +5.5% |
| FY Dec 2024 | +3.8% |
| FY Dec 2023 | +4.1% |
| FY Dec 2022 | +3.6% |
| FY Dec 2021 | +3.5% |
| Sep 2026 | +5.1% |
| Jun 2026 | +5.9% |
| Mar 2026 | +5.9% |
| Dec 2025 | +5.5% |
| Sep 2025 | +4.9% |
| Jun 2025 | +4.3% |
| Mar 2025 | +3.5% |
| Dec 2024 | +3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
98.50x
P/E over trailing EPS growth of 0%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing MRSH
| FY Dec 2025 | 7.51x |
| FY Dec 2024 | 2.96x |
| FY Dec 2023 | 1.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.51x |
| Sep 2026 | 85.16x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 7.51x |
| Sep 2025 | 8.92x |
| Jun 2025 | 8.15x |
| Mar 2025 | 8.42x |
| Dec 2024 | 2.96x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $27.0B | $24.5B | $22.7B | $20.7B |
| Operating income | $6.2B | $5.8B | $5.3B | $4.3B |
| Net income | $4.2B | $4.1B | $3.8B | $3.0B |
| EPS (diluted) | 8.43 | 8.18 | 7.53 | 6.04 |
| Operating cash flow | $5.3B | $4.3B | $4.3B | $3.5B |
| Cash | $2.7B | $2.4B | $3.4B | $1.4B |
| Long-term debt | $18.3B | $19.4B | $11.8B | $11.2B |
| Buybacks | $2.0B | $900.0M | $1.1B | $1.9B |
| Dividends paid | $1.7B | $1.5B | $1.3B | $1.1B |
SEC XBRL, fiscal years, as known on 2026-10-27
MRSH Stock Sonar score 6/7 axes
Find similar shapesCompareMRSH ranks highest on profitability (77th percentile) and risk and compliance (76th), and lowest on insider conviction (15th), among Insurance peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MRSH filings, in plain words
Are Marsh & Mclennan Companies insiders buying or selling MRSH?
In the 180 days to 2026-10-27, Marsh & Mclennan Companies insiders were net sellers, a net $12.0M across purchases and sales reported on Form 4, by 8 sellers.
Have members of Congress traded MRSH?
Yes. In the year to 2026-10-27, 0 House members disclosed buying MRSH and 1 House member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-23.
Are there planned insider sales of MRSH?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $5.8M of stock; the latest, by Klisura Dean Michael, was filed 2026-10-23.
Read the full summary
In the 180 days to 2026-10-27, Marsh & Mclennan Companies insiders were net sellers of MRSH, a net $12.0M across purchases and sales reported on Form 4 by 8 sellers. 33% of the 9 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 0 members of Congress disclosed buying MRSH and 1 member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-23. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $5.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
